Aktis Oncology (AKTS) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.54
- Estimate
- -$0.45
- Surprise
- -19.0%
- Revenue (period 2026-09-30)
- $3.9M
- Score today
- 5.9/10
Revenue source: xbrl.
How the report landed
Aktis Oncology (AKTS) reported a wider loss than forecast — adjusted EPS of -$0.54 against the -$0.45 estimate (a 19.0% shortfall).
Coverage in the report window
- Aktis Oncology Reports Third-Quarter 2026 Financial Results and Clinical Progress — fiscal.ai, 2026-11-12
- Aktis Oncology Q3 EPS $(0.54) Misses $(0.48) Estimate, Sales $3.905M Miss $4.016M Estimate — benzinga, 2026-11-12
Where TrendMatrix's rating stands now
TrendMatrix currently rates AKTS Sell at 5.9/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -19.0% surprise compares with a +6.6% four-quarter average. Next scheduled report: 2027-03-29.
What argues against it
- Concentration risk — Pipeline: lead product candidate [225Ac]Ac-AKY-1189
- Quality below floor (1.9 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $16.62
- Price target
- $31.21
- Stop
- $15.46
- Upside to target
- +87.8%
- Reward-to-risk
- 5.8:1
Model outputs from TrendMatrix’s engine as of 2026-11-15 — shown for context, not personalized investment advice.
AKTS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $927.4M
- P/E (fwd)
- -7.5
- 52-week range
- $13.96–$34.19
- Off 52-week high
- 51.4%
- RSI (14)
- 55
- Volume vs avg
- 0.72×
- Score today
- 5.9/10